BridgeBio Pharma stock gains 1.24 percent after FDA review news

Published on 10/07/2026 at 00:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BridgeBio Pharma stock now faces a February 4, 2027 FDA action date after Priority Review for infigratinib. Q2 2026 revenue reached USD 243.7 million, up 120 percent year over year.

BBIO, US10806X1028, Illustration mit AI erstellt.

BridgeBio Pharma stock (ISIN US10806X1028) was last at USD 66.96 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, up 1.24 percent. The move followed the company's announcement that the FDA accepted its oral infigratinib application for Priority Review in children with achondroplasia, as BioSpace reported on October 6, 2026.

FDA decision gets a date

The FDA assigned a February 4, 2027 PDUFA target action date for oral infigratinib. BridgeBio said it is prepared for a U.S. launch if the treatment wins approval, while a European marketing application is planned for the fourth quarter of 2026.

The application is based on the Phase 3 PROPEL 3 study. According to BioSpace, the trial produced a 2.10 cm per year mean treatment difference in annualized height velocity at Week 52, with p less than 0.0001. The same study also met its key secondary endpoint for height Z-score.

Revenue gives the pipeline support

BridgeBio's commercial base provides a second part of the valuation story. In Q2 2026, revenue reached USD 243.7 million, up 120 percent from the prior-year quarter, while U.S. Attruby net product revenue rose from USD 71.5 million to USD 222.4 million, according to Yahoo Finance.

The quarter still carried a loss. BridgeBio reported adjusted? No, the reported diluted loss was USD 0.78 per share in Q2 2026, compared with a USD 0.95 loss in the year-ago quarter, while cash, cash equivalents and marketable securities totaled USD 720.2 million on June 30, 2026. The July 1 preferred financing lifted the pro forma cash balance to USD 1.7 billion, according to Yahoo Finance.

Analysts see upside

Jefferies reiterated a Buy rating with a USD 110.00 price target on October 5, 2026. The target lies 64.3 percent above the USD 66.96 price, while the consensus rating was Strong Buy with targets from USD 80 to USD 157, according to Investing.com. The FDA decision remains the key test for turning clinical results into a commercial product.

BridgeBio stock stays below its yearly high

BridgeBio Pharma stock was last at USD 66.96 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. Its 52-week range was USD 52.75 to USD 93.42, placing the price 28.3 percent below the high.